Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2008 Jun;69(3):181–191. doi: 10.1016/j.curtheres.2008.06.009

Role of selective cyclooxygenase-2 inhibitors in exacerbation of inflammatory bowel disease: A systematic review and meta-analysis

Xin-Pu Miao 1, Qin Ouyang 1,a, Hui-Yan Li 2, Zhong-Hui Wen 1, De-Kui Zhang 1, Xiao-Yan Cui 3
PMCID: PMC3969923  PMID: 24692797

Abstract

Background: In the general population, selective cyclooxygenase (COX)-2 inhibitors have been associated with fewer gastrointestinal adverse effects (AEs) than NSAIDs, but whether they are associated with exacerbations in patients with inflammatory bowel disease (IBD) remains controversial.

Objective: The aim of this study was to review published and unpublished findings to determine whether the use of COX-2 inhibitors increased the risk for IBD exacerbations relative to placebo in the treatment of IBD.

Methods: A systematic search of MEDLINE (1966-July 2007), EMBASE (1980-July 2007), the Cochrane Library (2007 Issue 4), US Food and Drug Administration records, and data on file at Novartis Pharmaceuticals Corporation, Pfizer US Pharmaceutical Group, and Merck & Co., Inc., using the search terms celecoxib, rofecoxib, valdecoxib, etoricoxib, lumiracoxib, cyclooxygenase 2 inhibitor, Crohn's disease, ulcerative colitis, and inflammatory bowel disease, was performed to identify randomized, placebo-controlled clinical trials of 5 COX-2 inhibitors in patients with IBD. The publications were fully reviewed for quality. Data on trial design, patient characteristics, intervention drugs, dosages, and outcomes were collected using a predetermined data-extraction form. A meta-analysis was performed based on the publications that met the inclusion/exclusion criteria.

Results: Of 588 studies identified in the electronic search, 574 were excluded after screening the titles and abstracts. Fourteen related to the use of COX-2 inhibitors in patients with IBD were reviewed. Two randomized, controlled trials comparing COX-2 inhibitors with placebo were identified. In the first trial, 82 patients were randomized to receive etoricoxib (60–120 mg/d) and 77 to receive placebo. The exacerbation rates were 10.5% (8/76) in the active-treatment group and 11.4% (8/70) in the placebo group (relative risk [RR], 0.92; 95% CI, 0.37–2.32). In the second trial, 112 patients were treated with celecoxib (200 mg BID) and 110 received placebo. The exacerbation rates were 3.7% (4/107) in the celecoxib group and 2.7% (3/110) in the placebo group (RR, 0.73; 95% CI, 0.17–3.18). Of these patients, 5 were lost to follow-up because of AEs. In the meta-analysis comparing COX-2 inhibitors and placebo, the RR was 0.86 (95% CI, 0.39–1.88). No statistically significant differences in IBD relapse rates were found between COX-2 inhibitors and placebo.

Conclusions: The results from this meta-analysis suggest that insufficient data were available to determine the impact of COX-2 inhibitors on IBD exacerbations. The relatively smaller risk for AEs makes the short-term use of COX-2 inhibitors potentially attractive, but the long-term benefits remain unclear. Further studies with sound methodology and large sample sizes are needed to evaluate the tolerability of COX-2 inhibitors in the treatment of IBD.

Key Words: meta-analysis, cyclooxygenase-2 inhibitor, Crohn's disease, ulcerative colitis, inflammatory bowel disease

Full Text

The Full Text of this article is available as a PDF (630.4 KB).

References

  • 1.Loftus EV., Jr Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–1517. doi: 10.1053/j.gastro.2004.01.063. [DOI] [PubMed] [Google Scholar]
  • 2.Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am. 1999;28:255–281. doi: 10.1016/s0889-8553(05)70056-x. [DOI] [PubMed] [Google Scholar]
  • 3.Fiocchi C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology. 1998;115:182–205. doi: 10.1016/s0016-5085(98)70381-6. [DOI] [PubMed] [Google Scholar]
  • 4.Isaacs KL, Lewis JD, Sandborn WJ. State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis. 2005;11(Suppl 1):S3–S12. doi: 10.1097/01.mib.0000184852.84558.b2. [DOI] [PubMed] [Google Scholar]
  • 5.MacDonald TM, Morant SV, Robinson GC. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: Cohort study. BMJ. 1997;315:1333–1337. doi: 10.1136/bmj.315.7119.1333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Griffin MR, Scheiman JM. Prospects for changing the burden of nonsteroidal anti-inflammatory drug toxicity. Am J Med. 2001;110(Suppl):33S–37S. doi: 10.1016/s0002-9343(00)00634-3. [DOI] [PubMed] [Google Scholar]
  • 7.Silverstein FE, Graham DY, Senior JR. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241–249. doi: 10.7326/0003-4819-123-4-199508150-00001. [DOI] [PubMed] [Google Scholar]
  • 8.Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology. 1993;104:1832–1847. doi: 10.1016/0016-5085(93)90667-2. [DOI] [PubMed] [Google Scholar]
  • 9.Felder JB, Korelitz BI, Rajapakse R. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: A case-control study. Am J Gastroenterol. 2000;95:1949–1954. doi: 10.1111/j.1572-0241.2000.02262.x. [DOI] [PubMed] [Google Scholar]
  • 10.Forrest K, Symmons D, Foster P. Systematic review: Is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease? Aliment Pharmacol Ther. 2004;20:1035–1043. doi: 10.1111/j.1365-2036.2004.02270.x. [DOI] [PubMed] [Google Scholar]
  • 11.Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: A study of 700 patients. Medicine (Baltimore) 1976;55:401–412. doi: 10.1097/00005792-197609000-00004. [DOI] [PubMed] [Google Scholar]
  • 12.Rankin GB. Extraintestinal and systemic manifestations of inflammatory bowel disease. Med Clin North Am. 1990;74:39–50. doi: 10.1016/s0025-7125(16)30585-5. [DOI] [PubMed] [Google Scholar]
  • 13.Crofford LJ, Lipsky PE, Brooks P. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum. 2000;43:4–13. doi: 10.1002/1529-0131(200001)43:1<4::AID-ANR2>3.0.CO;2-V. [DOI] [PubMed] [Google Scholar]
  • 14.Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232–235. doi: 10.1038/newbio231232a0. [DOI] [PubMed] [Google Scholar]
  • 15.Bombardier C, Laine L, Reicin A, VIGOR Study Group Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520–1528. doi: 10.1056/NEJM200011233432103. [DOI] [PubMed] [Google Scholar]
  • 16.Schnitzer TJ, Burmester GR, Mysler E. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Randomized controlled trial. Lancet. 2004;364:665–674. doi: 10.1016/S0140-6736(04)16893-1. [DOI] [PubMed] [Google Scholar]
  • 17.Reinisch W, Miehsler W, Dejaco C. An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. Aliment Pharmacol Ther. 2003;17:1371–1380. doi: 10.1046/j.1365-2036.2003.01596.x. [DOI] [PubMed] [Google Scholar]
  • 18.Bonner GF. Exacerbation of inflammatory bowel disease associated with use of celecoxib. Am J Gastroenterol. 2001;96:1306–1308. doi: 10.1111/j.1572-0241.2001.03730.x. [DOI] [PubMed] [Google Scholar]
  • 19.Gornet JM, Hassani Z, Modiglian R, Lémann M. Exacerbation of Crohn's colitis with severe colonic hemorrhage in a patient on rofecoxib. Am J Gastroenterol. 2002;97:3209–3210. doi: 10.1111/j.1572-0241.2002.07142.x. [DOI] [PubMed] [Google Scholar]
  • 20.Biancone L, Tosti C, Geremia A. Rofecoxib and early relapse of inflammatory bowel disease: An open-label trial. Aliment Pharmacol Ther. 2004;19:755–764. doi: 10.1111/j.1365-2036.2004.01907.x. [DOI] [PubMed] [Google Scholar]
  • 21.Matuk R, Crawford J, Abreu MT. The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:352–356. doi: 10.1097/00054725-200407000-00005. [DOI] [PubMed] [Google Scholar]
  • 22.Guidance, information sheets, and important notices on good clinical practice in FDA-regulated clinical trials. May 30, 2008. http://www.fda.gov/oc/gcp/guidance.html [US Food and Drug Administration Web site] Accessed.
  • 23.Jadad AR, Moore RA, Carroll D. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17:1–12. doi: 10.1016/0197-2456(95)00134-4. [DOI] [PubMed] [Google Scholar]
  • 24.El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective COX-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol. 2006;101:311–317. doi: 10.1111/j.1572-0241.2006.00384.x. [DOI] [PubMed] [Google Scholar]
  • 25.Sandborn WJ, Stenson WF, Brynskov J. Safety of celecoxib in patients with ulcerative colitis in remission: A randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol. 2006;4:203–211. doi: 10.1016/j.cgh.2005.12.002. [DOI] [PubMed] [Google Scholar]
  • 26.Goh J, Wight D, Parkes M. Rofecoxib and cytomegalovirus in acute flare-up of ulcerative colitis: Coprecipitants or coincidence? Am J Gastroenterol. 2002;97:1061–1062. doi: 10.1111/j.1572-0241.2002.05631.x. [DOI] [PubMed] [Google Scholar]
  • 27.Freedman GM, Kreitzer JM, Badola R. Rofecoxib-associated upper gastrointestinal bleed: A case report. Mt Sinai J Med. 2002;69:105–106. [PubMed] [Google Scholar]
  • 28.Mahadevan U, Loftus EV, Jr, Tremaine WJ, Sandborn WJ. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol. 2002;97:910–914. doi: 10.1111/j.1572-0241.2002.05608.x. [DOI] [PubMed] [Google Scholar]
  • 29.Charachon A, Petit T, Lamarque D, Soulé JC. Acute ulcerative colitis in a patient treated with rofecoxib who took aspirin as self medication. Gastroenterol Clin Biol. 2003;27:511–513. [PubMed] [Google Scholar]
  • 30.Wilcox GM, Mattia AR. Rofecoxib and inflammatory bowel disease: Clinical and pathologic observations. J Clin Gastroenterol. 2005;39:142–143. [PubMed] [Google Scholar]
  • 31.Rey P, Andriamanantena D, Carrère C. Ulcerating haemorrhagic colitis induced by celecoxib [in French] Presse Med. 2005;34:443–445. doi: 10.1016/s0755-4982(05)83940-5. [DOI] [PubMed] [Google Scholar]
  • 32.Takeuchi K, Smale S, Premchand P. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:196–202. doi: 10.1016/s1542-3565(05)00980-8. [DOI] [PubMed] [Google Scholar]
  • 33.Towheed TE. Published meta-analyses ofpharmacological therapies for osteoarthritis. Osteoarthritis Cartilage. 2002;10:836–837. doi: 10.1053/joca.2002.0841. [DOI] [PubMed] [Google Scholar]
  • 34.Eccles M, Freemantle N, Mason J, North of England Non-Steroidal Anti-Inflammatory Drug Guideline Development Group North of England evidence based guideline development project: Summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. BMJ. 1998;317:526–530. doi: 10.1136/bmj.317.7157.526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Lee C, Hunsche E, Balshaw R. Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: Case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis. Arthritis Rheum. 2005;53:510–518. doi: 10.1002/art.21328. [DOI] [PubMed] [Google Scholar]
  • 36.Langman MJ, Jensen DM, Watson DJ. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999;282:1929–1933. doi: 10.1001/jama.282.20.1929. [DOI] [PubMed] [Google Scholar]
  • 37.Silverstein FE, Faich G, Goldstein JL, Celecoxib Long-Term Arthritis Safety Study Group Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. JAMA. 2000;284:1247–1255. doi: 10.1001/jama.284.10.1247. [DOI] [PubMed] [Google Scholar]
  • 38.McKenna F, Weaver A, Fiechtner JJ. COX-2 specific inhibitors in the management of osteoarthritis of the knee: A placebo-controlled, randomized, double-blind study. J Clin Rheumatol. 2001;7:151–159. doi: 10.1097/00124743-200106000-00004. [DOI] [PubMed] [Google Scholar]
  • 39.Gibofsky A, Williams GW, McKenna F, Fort JG. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: Appropriate trial design considerations and results of a randomized, placebo-controlled trial. Arthritis Rheum. 2003;48:3102–3111. doi: 10.1002/art.11330. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES